In addition, Kaplan–Meier survival analysis showed that patients who had TRIM22-positive gastric cancer had a better prognosis than those with TRIM22-negative cancer with a median survival of 50.0 months vs. 29.0 months. Here, TRIM22 is linked to gastric cancer.